Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic study Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly

NCT00532116
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg, EMSAM (Selegiline Transdermal System) 12mg
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers

NCT01430065
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Drug Interactions, Healthy Subjects
Interventions
ASP015K, Tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

NCT05541471
View directory record Official record
Conditions
Pain
Interventions
VX-548, Midazolam, Digoxin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Two Formulations of Lamotrigine in Healthy Subjects

NCT00410371
View directory record Official record
Conditions
Mental Disorders
Interventions
Lamotrigine, GI267119
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 19, 2026, 5:45 AM EDT
Active, not recruiting Early Phase 1 Interventional

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

NCT01269593
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Myeloma, Active Solid Malignancy
Interventions
PET Imaging using 124 IPUH71
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00095914
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents

NCT02201342
View directory record Official record
Conditions
Single Ventricle Heart Disease After Fontan Surgery
Interventions
Udenafil
Drug
Lead sponsor
Mezzion Pharma Co. Ltd
Industry
Eligibility
14 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

NCT00979173
View directory record Official record
Conditions
Glioma
Interventions
AC480
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580
View directory record Official record
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects

NCT07364669
View directory record Official record
Conditions
Healthy Subjects
Interventions
Insulex® R (soluble human insulin, biosimilar), Humulin® R (soluble human insulin, biosimilar)
Drug
Lead sponsor
Laboratorios Pisa S.A. de C.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

NCT02611024
View directory record Official record
Conditions
Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
Interventions
Lurbinectedin, Irinotecan
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Santa Monica, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers

NCT01375946
View directory record Official record
Conditions
Healthy
Interventions
AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients

NCT00002403
View directory record Official record
Conditions
HIV Infections
Interventions
Zintevir
Drug
Lead sponsor
Aronex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

NCT00937027
View directory record Official record
Conditions
Psoriasis
Interventions
Aminopterin
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
21 Years to 59 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 19, 2026, 5:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DYNE-251, Placebo
Drug
Lead sponsor
Dyne Therapeutics
Industry
Eligibility
4 Years to 16 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

NCT02062203
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 3 Interventional

INFUSE Morphine Study

NCT00593281
View directory record Official record
Conditions
Pain
Interventions
Hylenex
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Oct 19, 2026, 5:45 AM EDT
Completed No phase listed Observational

Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort

NCT01070719
View directory record Official record
Conditions
Multiple Sclerosis, Relapse
Interventions
Not listed
Lead sponsor
John F. Foley, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

NCT04760691
View directory record Official record
Conditions
HIV, Prophylaxis, Transgender
Interventions
Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg, Truvada plus Estradiol 6 mg, Estradiol 6 mg alone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 19, 2026, 5:45 AM EDT
Terminated Phase 1 Interventional

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

NCT03502577
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
BCMA-specific CAR-expressing T Lymphocytes, Cyclophosphamide, Fludarabine, Gamma-Secretase Inhibitor LY3039478, Laboratory Biomarker Analysis, Pharmacokinetic Study
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Vivitrol in Healthy Participants

NCT04716881
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Naltrexone 380 MG
Drug
Lead sponsor
Go Medical Industries Pty Ltd
Industry
Eligibility
18 Years to 57 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 19, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function

NCT01186588
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
Canagliflozin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 19, 2026, 5:45 AM EDT